

UNITED STATES DISTRICT COURT  
DISTRICT OF NEW JERSEY

IN RE: PROTON-PUMP  
INHIBITOR PRODUCTS  
LIABILITY LITIGATION (NO. II)

2:17-md-2789-CCC-LDW  
(MDL 2789)  
and all member and related cases

This Document Relates to:

Judge Claire C. Cecchi

*Bales v. AstraZeneca Pharmaceuticals LP*,  
No. 2:17-cv-06124

---

CASE MANAGEMENT ORDER NO. 98  
(Amended Pretrial Deadlines in *Bales*)

---

**I. Scope and Applicability**

This Case Management Order (“CMO”) is intended to conserve judicial resources, eliminate duplicative discovery, serve the convenience of the parties and witnesses, and promote the just and efficient conduct of this litigation. This CMO modifies certain deadlines set forth in the Parties’ Joint Stipulation and Order to Modify Certain Pretrial Deadlines Set Forth in CMO No. 83 and is entered with the consent of the parties.

**II. Pretrial Deadlines for *Bales***

A. Parties shall exchange on or before **March 24, 2023** their objections, with a brief explanation not to exceed 75 words for each objection, to the up to

50 priority exhibits for *Bales* designated by the other party.

B. Parties shall exchange on or before **March 24, 2023** their objections, with a brief explanation inserted as a bubble comment and not to exceed 75 words for each designation or counter-designation, to the designations and counter-designations for the 8 priority transcripts for *Bales* designated by the other party.

C. Parties shall exchange on or before **April 5, 2023** their responses, not to exceed 75 words per response, to the objections for the up to 50 priority exhibits for *Bales* designated by the other party. Each party shall also submit to the Court a spreadsheet with copies of the exhibits.

D. Parties shall exchange on or before **April 5, 2023** a response, with a brief explanation inserted as a bubble comment and not to exceed 75 words, to the objections to the designations and counter-designations for the 8 priority transcripts for *Bales* designated by the other party. Each party shall also submit to the Court copies of the transcripts with annotated comments as well as any implicated exhibits.

Consented to by:

/s/ Stephanie O'Connor

Stephanie O'Connor

Co-Lead Counsel, Plaintiffs' Steering Committee

Douglas & London, P.C.

59 Maiden Ln., 6th floor

New York, NY 10038

(212) 566-7500  
(212) 566-7501 (fax)  
soconnor@douglasandlondon.com

*Attorney for Plaintiff*

---

/s/ Beth S. Rose

Beth S. Rose  
William R. Stuart III  
SILLS CUMMIS & GROSS P.C.  
One Riverfront Plaza  
Newark, NJ 07102  
(973) 643-7000  
(973) 643-6500  
brose@sillscummis.com  
wstuart@sillscummis.com

*Attorneys for Takeda Development Center  
Americas, Inc. (d/b/a Takeda Global  
Research & Development Center, Inc.),  
Takeda Pharmaceuticals America, Inc.,  
Takeda Pharmaceutical Company Limited,  
Takeda Pharmaceuticals U.S.A., Inc., and  
Abbott Laboratories*

**MCCARTER & ENGLISH, LLP**

/s/ Gregory J. Hindy

Gregory J. Hindy  
Natalie H. Mantell  
Four Gateway Center  
100 Mulberry Street  
Newark, NJ 07101-0652  
(973) 622-4444  
[ghindy@mccarter.com](mailto:ghindy@mccarter.com)  
[nmantell@mccarter.com](mailto:nmantell@mccarter.com)

/s/ James J. Freebery

James J. Freebery  
Makenzie Windfelder  
405 N. King Street, 8th Floor  
Wilmington, DE 19801  
(302) 984-6300  
[jfreebery@mccarter.com](mailto:jfreebery@mccarter.com)  
[mwindfelder@mccarter.com](mailto:mwindfelder@mccarter.com)

**/s/ Amy K. Fisher**

Amy K. Fisher  
Katherine D. Althoff  
Kimberly C. Metzger  
880 West Monon Green Blvd., Suite 101  
Carmel, IN 46032  
(973) 622-4444  
[afisher@mccarter.com](mailto:afisher@mccarter.com)  
[kalthoff@mccarter.com](mailto:kalthoff@mccarter.com)  
[kmetzger@mccarter.com](mailto:kmetzger@mccarter.com)

**/s/ John A. Camp**

John A. Camp  
2525 Ponce De Leon Blvd., Suite 300  
Coral Gables, FL 33134  
(786) 437-5780  
[jcamp@mccarter.com](mailto:jcamp@mccarter.com)

**ARNOLD & PORTER KAYE SCHOLER LLP**

**/s/ Arthur E. Brown**

Arthur E. Brown  
250 West 55th Street  
New York, NY 10019-9710  
(212) 836-8000  
[Arthur.Brown@arnoldporter.com](mailto:Arthur.Brown@arnoldporter.com)

*Attorneys for AstraZeneca Pharmaceuticals LP and AstraZeneca LP<sup>1</sup>*

---

<sup>1</sup> Defendant AstraZeneca LP dissolved as a legal entity on December 31, 2018.

**IT IS SO ORDERED**

SIGNED 16 day of March 2023

A handwritten signature in black ink, appearing to read 'Cc', is written above a horizontal line.

CLAIRE C. CECCHI  
United States District Judge